Device and method for encapsulated gene therapy

• US 6,027,721 A
• Filed: 05/20/1996
• Issued: 02/22/2000
• Est. Priority Date: 05/20/1996
• Status: Expired due to Term

• Current Assignee: Neurotech USA, Inc. (Woodbrook Group Holdings, Inc.)
• Original Assignee: Cytotherapeutics, Inc.
• Inventors: Aebischer, Patrick, Hammang, Joseph P.
• Primary Examiner(s): Campell, Bruce R.
• Assistant Examiner(s): REYNOLDS, DEBORAH J
• Application Number:
  US08/650,726
• Time in Patent Office: 1,373 Days
• Field of Search: 514/44, 424/93.1, 424/93.21, 424/93.2, 424/452, 435/325, 435/465
• US Class Current: 424/93.2
• CPC Class Codes: A61K 48/00 Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
• CPC Class Codes: A61P 35/00 Antineoplastic agents

Abstract

Methods and devices are provided for gene therapy using encapsulated packaging cell lines to deliver viral particles carrying at least one heterologous gene encoding at least one biologically active molecule.

Claims

1. A biocompatible capsule comprising:

a core comprising living packaging cells that secrete a viral vector for infection of a target cell, wherein the viral vector is a retroviral vector, the vector comprising a heterologous gene encoding a biologically active molecule operably linked to a promoter that regulates expression of the biologically active molecule in the target cell, the heterologous gene being no more than 8 kb in length; and

an external jacket surrounding said core, said jacket comprising a permeable biocompatible material, said material having a porosity selected to permit passage of retroviral vectors of 100 nm diameter thereacross, permitting release of said viral vector from said capsule.

2. The capsule of claim 1 wherein the core additionally comprises a matrix, the packaging cells being immobilized by the matrix.

3. The capsule of claim 1 wherein the jacket comprises a hydrogel or thermoplastic material.

4. The capsule of claim 1 wherein the gene encodes a biologically active molecule selected from the group consisting of anti-proliferative agents, apoptosis-inducing molecules, bacterial toxins, tumor suppressor molecules, and anti-apoptotic molecules.

5. The capsule of claim 1 wherein the packaging cells are conditionally immortalized.

6. A method for making a biocompatible capsule for delivery of a viral vector, comprising the steps of:

selecting a jacket, the jacket comprising a biocompatible material having a porosity selected to permit passage of retroviral vectors of 100 nm diameter thereacross, permitting release of the retroviral vector,

loading packaging cells into the jacket, the packaging cells secreting said viral vector comprising a heterologous gene encoding at least one biologically active molecule operably linked to a promoter that regulates expression of the biologically active molecule in the target cell and being no more than 8 kb in length; and

sealing the jacket to encapsulate the packaging cells.

7. A method of delivering a viral vector to a cell in vitro by placing at least one capsule in proximity with the cell, said capsule comprising:

a core comprising living packaging cells that secrete the viral vector, wherein the viral vector is a retroviral vector, the vector comprising a heterologous gene encoding a biologically active molecule operably linked to a promoter that regulates expression of the biologically active molecule in said cell, the heterologous gene being no more than 8 kb in length; and

an external jacket surrounding said core, said jacket comprising a biocompatible material, said material having a porosity selected to permit passage of retroviral vectors of 100 nm diameter thereacross, permitting release of the viral vector from the capsule.

8. The method of claim 7 wherein the core additionally comprises a matrix, the packaging cells being immobilized by the matrix.

9. The method of claim 7 wherein the jacket comprises a hydrogel or thermoplastic material.

10. The method of claim 7 wherein the gene encodes a biologically active molecule selected from the group consisting of anti-proliferative agents, apoptosis-inducing molecules, bacterial toxins, tumor suppressor molecules, and anti-apoptotic molecules.

11. The method of claim 7 wherein said viral vector comprises a gene useful in the treatment of human tumors or cancers, or cell proliferation disorders.

12. The method of claim 7 wherein the viral vector is a replication deficient retroviral vector.

13. The method of claim 7 wherein said viral vector comprises a gene selected from the group consisting of GMCSF and HSV-tk and which method further comprises administration of ganciclovir to the cell.

14. The method of claim 7 wherein the capsule further comprises a tether for the retrieval of said capsule, and the method comprises the additional step of removing the capsule from proximity with the cell after delivery of the retroviral vector.

15. The method of claim 7 wherein the packaging cells are conditionally immortalized.

16. A method of delivering a viral vector to a cell by placing at least one capsule in proximity with the cell, said capsule comprising:

a core comprising living packaging cells that secrete the viral vector, wherein the viral vector is a retroviral vector, the vector comprising a heterologous gene encoding a biologically active molecule operably linked to a promoter that regulates expression of the biologically active molecule in said cell, wherein the heterologous gene is HSV-tk; and

an external jacket surrounding said core, said jacket comprising a biocompatible material, said material having a porosity selected to permit passage of retroviral vectors of 100 nm diameter thereacross, permitting release of the viral vector from the capsule.

17. The method of claim 16 wherein the core additionally comprises a matrix, the packaging cells being immobilized by the matrix.

18. The method of claim 16 wherein the jacket comprises a hydrogel or thermoplastic material.

19. The method of claim 16 wherein the capsule is placed in proximity with the cell in vitro.

20. The method of claim 16 wherein the capsule further comprises a tether for the retrieval of said capsule, and the method comprises the additional step of removing the capsule from proximity with the cell after delivery of the retroviral vector.

21. The method of claim 16 wherein the packaging cells are conditionally immortalized.